BiomX develops customized phage therapies that target harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer.

  May 15, 2017| BiomX Ltd., an Israeli microbiome therapeutics company, announced today that it has raised $24 million in a Series A funding round. The round was led by OrbiMed, Johnson & Johnson Innovation – JJDC, Inc. and Takeda Ventures, Inc. with participation from Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors. […]